Eli Lilly and Company (NYSE:LLY) Stake Decreased by Dorsey Wright & Associates

Dorsey Wright & Associates lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 97.2% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 468 shares of the company's stock after selling 16,101 shares during the period. Dorsey Wright & Associates' holdings in Eli Lilly and Company were worth $387,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BG Investment Services Inc. acquired a new position in Eli Lilly and Company during the 1st quarter worth approximately $221,000. Noesis Capital Mangement Corp increased its position in Eli Lilly and Company by 32.8% during the 1st quarter. Noesis Capital Mangement Corp now owns 409 shares of the company's stock worth $338,000 after purchasing an additional 101 shares during the period. Guardian Wealth Management Inc. increased its position in Eli Lilly and Company by 0.5% during the 1st quarter. Guardian Wealth Management Inc. now owns 7,564 shares of the company's stock worth $6,247,000 after purchasing an additional 39 shares during the period. Black Swift Group LLC grew its holdings in shares of Eli Lilly and Company by 65.7% in the 1st quarter. Black Swift Group LLC now owns 1,897 shares of the company's stock worth $1,567,000 after acquiring an additional 752 shares during the period. Finally, Dempze Nancy E grew its holdings in shares of Eli Lilly and Company by 11.5% in the 1st quarter. Dempze Nancy E now owns 2,374 shares of the company's stock worth $1,961,000 after acquiring an additional 244 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.8%

Shares of Eli Lilly and Company stock traded up $6.30 during trading hours on Friday, hitting $811.73. 2,976,064 shares of the company's stock traded hands, compared to its average volume of 2,810,305. The stock has a 50 day simple moving average of $771.95 and a 200-day simple moving average of $800.51. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The company has a market cap of $769.30 billion, a PE ratio of 66.05, a PEG ratio of 1.18 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the previous year, the business posted $2.58 EPS. The business's revenue for the quarter was up 45.2% on a year-over-year basis. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.74%. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target on the stock. UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.